



Financial Tear Sheet


Corporate Profile

G1 Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for the treatment of cancer. Two of the company’s pipeline assets, trilaciclib and G1T38, are CDK4/6 inhibitors, a validated and promising class of oncology therapeutics. Trilaciclib and G1T38 have broad therapeutic potential in many forms of cancer and may serve as backbone therapy of multiple combination regimens. Trilaciclib is a short-acting IV CDK4/6 inhibitor designed to preserve hematopoietic stem cell and immune system function (myelopreservation) during chemotherapy. G1T38 is a potential best-in-class oral CDK4/6 inhibitor for use in combination with other targeted therapies. G1 is also advancing G1T48, a potential best-in-class oral selective estrogen receptor degrader, or SERD, which is targeted for the treatment of ER+ breast cancer. G1 owns or holds an exclusive license for worldwide commercial rights to each of its product candidates.

Stock Performance

GTHX (Common Stock)

Exchange	NASDAQ GS (US Dollar)
Price	\$50.91
Change (%)	▲ 2.60 (5.38%)
Volume	264,364
52 Week Low	\$12.04
Market Cap	\$1,664,025,678
Rolling EPS	-2.48
PE Ratio	0
Shares Outstanding	32,685,635



Data as of 05/18/18 4:00 p.m. ET

Recent Headlines

05/16/18

G1 Therapeutics to Present Phase 1b Data on G1T38 in Combination with Faslodex for Treatment of Breast Cancer at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

05/03/18

G1 Therapeutics Provides First Quarter 2018 Corporate and Financial Update

05/01/18

G1 Therapeutics to Present at UBS Global Healthcare Conference in May 2018

Recent Events

Date	Title
05/22/18 10:00 a.m. ET	G1 Therapeutics, Inc. at the UBS Global Healthcare Conference

SEC Filings

Filing Date	Form	Description
05/16/18	4	Statement of changes in beneficial ownership of securities
05/16/18	4	Statement of changes in beneficial ownership of securities
05/07/18	4	Statement of changes in beneficial ownership of securities
05/03/18	10-Q	Quarterly report which provides a continuing view of a company's financial position

Data provided by Nasdaq. Minimum 15 minutes delayed. View [Attributions and Sources](#)